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Abstract
Background: Inequalities in cancer research participation are thought to exist with certain groups under-represented
in research populations; however, much of the evidence is based on small-scale studies. The aim of this study was to
explore data from in-depth interviews with cancer patients and a large national survey to investigate variation in who
is asked to participate in research and who takes part.
Methods: Factors associated with research discussion and participation were explored in National Cancer Patient
Experience Survey data using multivariate logistic regression and during in-depth interviews with 25 breast cancer
patients.
Results: Survey data were available for 66,953 cancer patients; 30.4 % reported having discussions about, and 18.9 %
took part in, research. Barriers to participation at staff, patient and trust level were evident; for example, staff were less
likely to discuss research with older patients, Asian and black patients were less likely to take part and patients treated
at specialist or teaching trusts had higher levels of discussion and participation. Interviews showed that patients’
willingness to participate changed over time and was not synonymous with participation as some were ineligible.
Conclusion: Some patient groups were less likely to have discussions about or participate in research. Analysis of this
variation vis-à-vis the composition of the patient population may be useful to ensure that there is equity regarding the
potential benefits of research participation and that research findings are applicable to target populations in the
translational model.
Background
Translational research has two phases; the first transfers
knowledge from basic research (the “bench”) to clinical
research, while the second transfers findings from clin-
ical research (i.e. studies or trials) into practice (the
“bedside”) [1]. Under this translational model, advances
in cancer care and treatment necessitate patient partici-
pation in research activities so that findings observed in
a trial population may be rapidly translated into benefits
for the wider patient population. Studies have also
shown that patients may benefit directly from participa-
tion in research studies, for example, in terms of better
clinical outcomes [2] and more positive patient experi-
ence [3]. Equitable access to research participation is
therefore important to ensure that research findings are
generalizable to the target population and that there is
fair access to the potential benefits associated with tak-
ing part in research.
Inequalities in access to cancer research are thought to
exist, with certain groups such as women [4], ethnic mi-
norities [5] and older patients [6] under-represented in
research populations. Some studies have indicated that
these inequalities may be attributable to staff level bar-
riers as researchers and clinicians may be less likely to
enrol certain groups of patients in trials [7]. They may
also be due to barriers at a patient level. Although some
studies have found no association between willingness
to participate and demographic or clinical characteristics
[8, 9], others have found that it may vary by patient charac-
teristics such as age, gender, ethnicity and educational sta-
tus [10, 11]. However, much of the evidence to date has
been based on research involving small numbers of
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patients. The National Cancer Patient Experience Survey
(NCPES) is a regular survey of patients treated for cancer
in NHS hospitals in England that contains questions about
patients’ experiences of care and treatment. It also contains
a question related to discussion about research participa-
tion and the NCPES 2012–13 introduced a follow-up ques-
tion about whether patients had taken part in cancer
research. This presented a unique opportunity to investi-
gate variation in who is asked to participate in research and
who takes part. We were able to further explore this mater-
ial through interviewing patients with breast cancer about
their knowledge, attitudes and participation in research.
Such information could be useful for identifying patient
groups who experience barriers to accessing research or are
less likely to participate and for informing the development
of targeted strategies aimed at improving equity of access
to research participation for all patients.
Methods
Source of data
Cross-sectional NCPES 2012–13 data collected on be-
half of the Department of Health was used for this ana-
lysis. All patients with a primary diagnosis of cancer who
attended an NHS hospital as an inpatient or day case be-
tween 1st September 2012 and 30th November 2012 were
sent the survey. A response rate of 64 % was achieved
overall and the dataset included 68,737 cancer patients
who attended 155 hospital trusts across England [12].
Patient, clinical and trust level characteristics
Patient level characteristics were ascertained by self-
report where possible and grouped as in the national
NCPES report [12]. Gender, age, ethnicity and employ-
ment status were derived from patients’ survey responses
with males chosen as the reference category for gender
and the largest groups chosen for the other factors.
Patients with co-morbidities were identified through
responses to the question “Do you have any of the fol-
lowing long-standing conditions?” and the reference cat-
egory for each specific long-standing condition was not
having that condition. Patients’ clinical characteristics
were taken from hospital administration records (i.e.
tumour group and day case or inpatient status) or were
self-reported (i.e. time since first treatment and response
to treatment) and hospital trusts were categorised by
foundation status, location (in or outside London) and
type (large acute, medium acute, small acute, specialist
and teaching). Breast was chosen as the reference
tumour group as these patients had the highest rate of
trial discussion, and therefore the group against which
we wished to contrast other tumour groups. The largest
groups were chosen as reference categories for all other
clinical and trust level factors.
Survey questions
In addition to demographic and clinical characteristics, the
dataset contained patients’ responses to two questions re-
lated to cancer research discussion and participation. A
positive response to the question “Since your diagnosis, has
anyone discussed with you whether you would like to take
part in cancer research?” was used as the binary outcome
to investigate potential inequalities in research discussion
among cancer patients. This question was answered by
66,953 patients; the small proportion of patients who pro-
vided no response (3 %, n = 1,784) were excluded from this
analysis (Fig. 1). Responses to the recently added question
“If yes, did you then go on to take part in cancer research?”
were used as a binary outcome to investigate potential vari-
ation in research participation among cancer patients. Pa-
tients who provided no response to this question were also
excluded from this analysis (n = 491).
Data analysis
To determine if there were inequalities in discussions
about participation in cancer research, univariate logistic
regression was used to describe associations between pa-
tient, clinical or trust level factors and having discussed
taking part in research. Multivariate logistic regression
was subsequently used to control for confounding. Simi-
larly, univariate and multivariate logistic regression were
used to describe the variation in who went on to partici-
pate in cancer research among those who reported having
discussions. All analyses were carried out using Stata v12.
Qualitative interviews
We used interview data from 25 women with breast can-
cer at a London trust to contextualise and understand
further the survey results. These interviews were carried
out as part of a larger qualitative study that aimed to de-
scribe how patient experience varies across the care
pathway and to inform strategies to improve care and
treatment. To be eligible for interview, patients had to
be ≥18 years of age and receiving treatment or follow-up
care for breast cancer between September 2012 and No-
vember 2012. During the interviews we used the NCPES
question, “Since your diagnosis, has anyone discussed
with you whether you would like to take part in cancer
research?” to introduce the topic of cancer research. In-
terviews were recorded and audio-transcribed and lasted
50–70 min. We then analysed patients’ narratives using
Nvivo software coding reasons for participating or not
participating in studies and attitudes towards, or experi-
ences of, cancer research.
Ethics
No ethical approval was required for the secondary ana-
lysis of pseudonymised quantitative survey data in this
study. Patients gave written consent for the interviews
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and the qualitative study had all local NHS research per-
missions and ethical approval (City & East Research Eth-
ics Committee: 12/LO/0685).
Results
Table 1 shows the characteristics of the 66,953 respon-
dents and the hospital trusts they attended. The majority
of patients were female, >50 years old, white, retired and
substantial numbers had disabilities or other long-
standing conditions. The largest tumour groups were
breast and haematological cancers. Most respondents
had started their treatment less than a year ago and were
admitted to hospital as a day case on their most recent
visit. More than a third reported that, at the time of
completing the survey, their cancer had responded fully
to treatment and they had no signs or symptoms of can-
cer. Most respondents were treated in large acute trusts
and trusts with foundation status.
Since your diagnosis, has anyone discussed with you
whether you would like to take part in cancer research?
Overall, 30.4 % of respondents (n = 20,356) reported
that, since their diagnosis, someone had discussed with
them whether they would like to take part in cancer re-
search. Associations between patient, clinical and trust
level characteristics and research participation being dis-
cussed are shown in Table 2. A higher proportion of
women, younger and non-white patients reported being
asked, but after controlling for factors such as tumour
group, female and older patients were significantly less
Fig. 1 Flow diagram of the number of respondents included in analysis. Number of National Cancer Patient Experience Survey 2012–13
respondents included at each stage of the analysis
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likely to have discussed participation. It was also less
likely in people with certain long-standing conditions in-
cluding mental health issues, physical conditions or
long-standing illnesses. Breast and urological cancer pa-
tients had the highest and lowest proportions of research
discussion, 35.9 and 15.4 % respectively, and breast can-
cer patients were significantly more likely to have had
discussions about research participation than patients
with other tumours, with the exception of colorectal/
lower gastrointestinal (GI), haematological and prostate
cancer patients. Finally, discussions were more likely to
have occurred among patients treated at trusts in
London and at specialist or teaching trusts, and less
likely among patients who began treatment in the last
year or who reported not having any treatment for their
cancer (ORadj:0.47; 95 % CI:0.38–0.59, p < 0.001). There
were no significant associations between research discus-
sion and ethnicity, employment status (data not shown),
day case or inpatient status (data not shown) or a trust’s
foundation status.
Did you go on to take part in cancer research?
Of the 20,356 patients with whom research participation
was discussed, 62.3 % (n = 12,682) reported that they
went on to take part. Associations between patient, clin-
ical and trust level characteristics and taking part in re-
search are shown in Table 3. A greater proportion of
men than women took part; however, when other pa-
tient, clinical and trust level factors were controlled for,
there were no statistically significant difference in re-
search participation by gender. An overall negative asso-
ciation between taking part in research and age was
observed, with older patients less likely to participate
than younger patients. Asian and black patients and
Table 1 Characteristics of NCPES 2012–13 respondents and the
hospital trusts they attended
Patient characteristics
Gender n % Long-standing conditions a n %
Male 31,376 46.9 None 38,982 58.2
Female 35,577 53.1 Deafness/hearing
impairment
6,839 10.2
Blindness/partially
sighted
1,494 2.2
Age group n % Physical condition 8,884 13.3
16–25 257 0.4 Learning disability 280 0.4
26–35 890 1.3 Mental health condition 1,319 2.0
36–50 6,086 9.1 Long-standing illness b 8,706 13.0
51–65 20,045 29.9
66–75 22,034 32.9 Employment status n %
76+ 14,951 22.3 Full-time 10,710 16.0
Part-time 5,792 8.7
Ethnicity n % Homemaker 1,771 2.7
White 61,991 92.6 Student 178 0.3
Mixed 316 0.5 Retired 40,195 60.0
Asian/Asian
British
1,155 1.7 Unemployed –
seeking work
459 0.7
Black/Black
British
894 1.3 Unemployed –
unable to work
3,725 5.6
Other 280 0.4 Other 1,391 2.1
Clinical characteristics
Tumour
group
n % Patient status n %
Brain/CNS 711 1.1 Day case 43,272 64.6
Breast 13,763 20.4 Inpatient 23,681 35.4
Colorectal/
Lower GI
8,636 12.9
Gynaecological
3,772 5.6 Time since first treatment n %
Haematological
11,321 16.9 <1 year 42,796 63.9
Head and
Neck
2,388 3.6 1–5 years 16,164 24.1
Lung 4,886 7.3 >5 years 5,511 8.2
Other 2,675 4.0
Prostate 5,418 8.1 Response to treatment c n %
Sarcoma 711 1.1 Full response (no signs/
symptoms)
23,926 35.7
Skin 1,785 2.7 Treated, but cancer still
present
16,800 25.1
Upper GI 4,186 6.3 Original cancer has
come back
3,500 5.2
Urological 6,803 10.2 Original cancer treated,
have new cancer
1,890 2.8
Have not received
treatment yet
1,098 1.6
Table 1 Characteristics of NCPES 2012–13 respondents and the
hospital trusts they attended (Continued)
Trust characteristics
Trust type n % Foundation status n %
Small acute 5,642 8.4 No 29,256 43.7
Medium acute 15,015 22.4 Yes 37,697 56.3
Large acute 23,510 35.1
Specialist 3,317 5.0 Location n %
Teaching 19,469 29.1 London 9,242 13.8
Outside London 57,711 86.2
Total number of respondents = 66,953. Age was unknown for 4.0 % of
respondents, ethnicity was unknown for 3.4 %, long-standing conditions status
for 8.5 %, employment status for 4.1 %, time since first treatment for 3.7 %
and response to treatment for 8.9 %
GI = gastrointestinal; CNS = central nervous system
a 6.5 % of patients (n = 4,379) had >1 long-standing condition, therefore the
column total exceeds 100 %
b Such as (but not limited to) HIV, diabetes, chronic heart disease or epilepsy
c 20.6 % of respondents were “uncertain about what was happening with
their cancer”
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those with certain long-standing illnesses were also less
likely to participate. Haematological and urological can-
cer patients had the highest and lowest proportions of
research participation, 71.7 % and 54.9 % respectively. In
comparison to breast cancer patients, haematological,
colorectal/lower GI, gynaecological and other cancer pa-
tients were significantly more likely to participate in re-
search. Patients who began their treatment over a year ago
were also more likely to take part in research than those
who had commenced treatment in the last year. There
was no significant difference in research participation by a
patient’s reported response to treatment, their day case/in-
patient status (data not shown) and the location or foun-
dation status of the trust they attended. Patients treated at
specialist or teaching trusts were however more likely to
take part.
Figure 2 presents the cascade of participation rates
based on the results of our multivariate analysis de-
scribed in Tables 2 and 3. In particular, this figure high-
lights the key role of specialist and teaching hospitals in
improving access to cancer research by facilitating more
discussions about participation and greater uptake
among patients. Combining both sets of results to look at
overall representation in research, we found that 26.9 %
of patients attending a specialist or teaching hospital took
part in research compared with 15.1 % of patients at-
tending acute hospitals (ORadj:1.97; 95 % CI:1.89–
2.06, p < 0.001). We also found that women, older
patients and those with comorbidities are under-rep-
resented in research as only 19.0 % of females took part in
research compared with 23.8 % of males (ORadj:0.85; 95
% CI:0.81–0.90, p < 0.001), 15.7 % of over-65 s compared
with 24.3 % of under-65 s (ORadj:0.60; 95 % CI:0.57–0.62,
p < 0.001) and 16.5 % of those with one or more long-
standing condition compared with 21.0 % of those
without any (ORadj:0.82; 95 % CI:0.80–0.85, p < 0.001).
Interviews with breast cancer patients
To understand more about research participation we
analysed data from breast cancer patient interviews. Of
the 25 women we interviewed, 17 had been asked if they
would like to participate in cancer research. Of these
women, ten had gone on to take part in a research study,
one had not yet decided and one was unsure if she had
participated or not. Participants ranged in age from 38
to 79 years (median: 58.7 years) and most were white
(n = 19). The majority of women were being treated
for first occurrences of breast cancer (n = 20) and
began treatment less than five years ago (n = 18).
Decisions about research were not taken in isolation;
they were often discussed with family and friends as well
as clinical staff, and taken in light of other treatment
decisions.
“Because you’re never sure. When you have cancer, or
anything wrong with you, you really rely on the
honesty of the people. So (the staff ) talked to me, and I
kind of - not agreed - but you don’t know what to say.
You don’t understand it. I said, “Whatever’s good for
me.” They said, “If it's true that you can take
something for six months, why take it for a year?”
[Participant 1]
As with other treatment decisions described by
these women, there was generally a conscious weigh-
ing up the potential benefits and costs. When, in the
patient’s opinion, the potential side effects of the re-
search outweighed the potential benefits, they chose
not to participate.
“It was something to do with taking tamoxifen before
the operation, but … that drug may have caused me
joint pain, and I didn’t want to take the chance.”
[Participant 2]
Some patients declined to participate in research
when the protocol conflicted with decisions they had
made or might make in the future about their care; for
example, one woman declined to join a chemotherapy
trial as she wanted hormone therapy. Others decided
not to participate because they could not cope at that
point in time, although some of them participated in
other studies subsequently, highlighting the fact that
the willingness to take part in research varies over the
course of treatment.
“Because at that time I wasn’t ready, I didn’t want to
talk about things, what happened to me. I was still
vulnerable at that time so I say – that’s why I always
decline, if anyone asks me if I can volunteer, because I
can’t bear it. At least it’s almost 2 years now, then I
am more ready” [Participant 3 who declined a service
evaluation interview immediately after her treatment
ended but went on to be interviewed as part of our
study a year later]
“They did try to get me onto a trial before my
operation. I found that quite difficult because I had
said no, and I felt the person was pushing me a bit,
but I still said no”. [Participant 2 who went on to take
part in two trials during chemotherapy and
radiotherapy]
Participation in a study is not determined solely by pa-
tients’ responses to these discussions; sometimes screen-
ing showed subsequently that patients were not well
enough to take part or that their previous treatments
precluded participation.
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Table 2 Characteristics associated with research discussion
Patient level factors
Gender n % OR 95 % CI p-value ORadj
a 95 % CI p-value
Male 9,348 28.9 (ref) (ref)
Female 11,008 30.9 1.05 1.01 – 1.08 0.01 0.85 0.80 – 0.89 < 0.001
Age group
16 – 25 98 38.1 1.51 1.16 – 1.96 0.002 1.41 0.96 – 2.07 0.08
26 – 35 317 35.6 1.27 1.10 – 1.46 0.001 1.14 0.97 – 1.34 0.11
36 – 50 2,249 37.0 1.32 1.24 – 1.40 < 0.001 1.15 1.05 – 1.27 0.004
51 – 65 7,267 36.3 1.27 1.22 – 1.32 < 0.001 1.18 1.11 – 1.25 < 0.001
66 – 75 6,802 30.9 (ref) (ref)
76+ 2,891 19.3 0.54 0.52 – 0.57 < 0.001 0.58 0.54 – 0.62 < 0.001
Ethnicity
White 18,662 30.1 (ref) (ref)
Mixed 132 41.8 1.72 1.37 – 2.17 < 0.001 1.29 0.97 – 1.72 0.08
Asian/Asian British 430 37.2 1.54 1.36 – 1.74 < 0.001 1.11 0.93 – 1.33 0.26
Black/Black British 361 40.4 1.71 1.48 – 1.96 < 0.001 1.09 0.91 – 1.30 0.35
Other 107 38.2 1.53 1.19 – 1.96 0.001 0.97 0.70 – 1.34 0.85
Long-standing conditions b
None 12,752 32.7
Deafness/hearing impairment 1,642 24.0 0.70 0.66 – 0.74 < 0.001 0.93 0.87 – 1.00 0.05
Blindness/partially sighted 347 23.2 0.69 0.61 – 0.78 < 0.001 0.92 0.81 – 1.05 0.20
Physical condition 2,483 27.9 0.86 0.81 – 0.90 < 0.001 0.92 0.87 – 0.97 0.003
Learning disability 82 29.3 1.04 0.80 – 1.35 0.78 0.88 0.63 – 1.22 0.43
Mental health condition 355 26.9 0.85 0.75 – 0.96 0.01 0.79 0.69 – 0.91 0.001
Long-standing illness c 2,269 26.1 0.78 0.74 – 0.82 < 0.001 0.88 0.83 – 0.94 < 0.001
Clinical level factors
Tumour group n % OR 95 % CI p-value ORadj
a 95 % CI p-value
Brain/CNS 255 35.4 1.02 0.88 – 1.20 0.77 0.69 0.53 – 0.88 0.004
Breast 4,870 35.9 (ref) (ref)
Colorectal / Lower GI 2,670 30.9 0.81 0.77 – 0.86 < 0.001 0.91 0.81 – 1.02 0.12
Gynaecological 1,016 26.9 0.67 0.62 – 0.73 < 0.001 0.64 0.55 – 0.75 < 0.001
Haematological 3,842 33.9 0.94 0.90 – 0.99 0.03 0.85 0.72 – 1.01 0.06
Head and Neck 659 27.6 0.71 0.64 – 0.78 < 0.001 0.59 0.47 – 0.73 < 0.001
Lung 1,443 29.5 0.77 0.72 – 0.83 < 0.001 0.71 0.59 – 0.85 < 0.001
Other 833 31.1 0.82 0.75 – 0.90 < 0.001 0.68 0.59 – 0.79 < 0.001
Prostate 1,785 32.9 0.88 0.83 – 0.95 < 0.001 0.90 0.76 – 1.07 0.24
Sarcoma 229 32.2 0.88 0.75 – 1.04 0.13 0.62 0.46 – 0.84 0.002
Skin 316 17.7 0.38 0.34 – 0.43 < 0.001 0.35 0.25 – 0.47 < 0.001
Upper GI 1,390 33.2 0.91 0.84 – 0.98 0.01 0.83 0.71 – 0.97 0.02
Urological 1,048 15.4 0.33 0.30 – 0.35 < 0.001 0.33 0.28 – 0.39 < 0.001
Time since 1st treatment
< 1 year 12,233 28.6 (ref) (ref)
1–5 years 5,721 35.4 1.41 1.35 – 1.46 < 0.001 1.44 1.34 – 1.55 < 0.001
> 5 years 1,781 32.3 1.23 1.15 – 1.30 < 0.001 1.30 1.19 – 1.42 < 0.001
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“I wasn’t eligible because one of the medications that
probably I would be taking, I’ve had it, which is what I
had for my chemotherapy. You need to have a
12 month gap, but it has not been a year yet, so I can’t
go on that one” [Participant 4]
As cancer care and research become ever more strati-
fied by tumour stage and grade, other women found that
they were not eligible to take part in research trials be-
cause they were not part of the “right” tumour group.
“The thing is, for my cancer, the research is not done
so much, for the triple-negative breast patient”
[Participant 5]
The often complex eligibility criteria for research trials
were not always clear to patients, or even staff. Patients
sometimes received contradictory information and had
discussions about taking part in a study only to be told
they were ineligible. For example, one patient with the
BRCA2 gene was willing to participate later that in a re-
search trial after discussion with a research nurse, only
to be told by the doctor that her tumour type made her
ineligible.
“It was a chemotherapy drug. My treatment wasn’t
working. [The research nurse] mentioned it. Then, I
mentioned it to [my consultant] and he said, “No, that
drug is just if you are triple negative.” When I saw the
research nurse again, I mentioned it and she said,
“No, it is if you are BRCA2 as well.” [Participant 6 was
willing to participate in the trial but did not pursue it
any further after being told she was ineligible by the
doctor]
Other factors such as trust in healthcare and bio-
medical research may also influence decisions. One
woman, whose husband had been treated for and
subsequently died of cancer at another hospital years
previously, did not want to participate in any bio-
medical research as she had misgivings about the
way that research was conducted and was suspicious
of the motivations of cancer researchers; although
she was happy to be involved in our qualitative
study of experiences aimed at improving care and
services.
“When my husband was having his treatment…
there were little old ladies there and I got the
feeling they could have been experimenting on them.
All this money that’s going into research… It doesn’t
seem to change really. We’re still here. My husband
died 20-odd years ago and there’s still no cure…
Maybe there is a cure, but is this some kind of in-
dustry that people get cosy in? What incentive is it
if you’re working in cancer and you’re getting a nice
salary? It’s affording your mortgage and you’re hav-
ing a good lifestyle.” [Participant 7]
Discussion
In this large national study, 30.4 % of cancer patients re-
ported having discussions about, and 18.9 % took part in,
Table 2 Characteristics associated with research discussion (Continued)
Trust level factors
Trust type n % OR 95 % CI p-value ORadj
a 95 % CI p-value
Small acute 1,384 24.5 0.99 0.92 – 1.06 0.71 1.01 0.88 – 1.18 0.85
Medium acute 3,931 26.2 1.07 1.02 – 1.12 0.01 1.08 0.95 – 1.23 0.20
Large acute 5,847 24.9 (ref) (ref)
Specialist 1,606 48.4 2.95 2.73 – 3.18 < 0.001 2.52 1.73 – 3.66 < 0.001
Teaching 7,588 39.0 1.99 1.91 – 2.07 < 0.001 1.97 1.71 – 2.27 < 0.001
Foundation status
No 8,581 29.3 (ref) (ref)
Yes 11,775 31.2 1.10 1.07 – 1.14 < 0.001 0.97 0.88 – 1.08 0.60
Location
Outside London 16,576 28.7
London 3,780 40.9 1.76 1.68 – 1.84 < 0.001 1.25 1.07 – 1.46 0.01
Table 2 shows the characteristics of respondents who had discussions about taking part in cancer research and the association of these characteristics with research
discussion by logistic regression. 5.3 % of respondents (n= 3,527) were unsure if staff had discussed taking part in research with them since their diagnosis
GI = gastrointestinal; CNS = central nervous system
aAdjusting for patient level (i.e. gender, age, ethnicity, specific longstanding conditions, sexual orientation, employment status), clinical level (i.e. tumour group,
time since first treatment, response to treatment) and trust level factors (i.e. trust type, foundation status, London location)
b The reference category for specific long-standing conditions was not having that long-standing condition
c Such as (but not limited to) HIV, diabetes, chronic heart disease or epilepsy
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Table 3 Characteristics associated with research participation
Patient level factors
Gender n % OR 95 % CI p-value ORadj
a 95 % CI p-value
Male 5,983 64.0 (ref) (ref)
Female 6,699 60.9 0.87 0.82 – 0.93 < 0.001 0.91 0.82 – 1.00 0.06
Age group
16 – 25 67 68.4 1.32 0.86 – 2.04 0.20 1.48 0.80 – 2.71 0.21
26 – 35 229 72.2 1.60 1.24 – 2.06 < 0.001 1.39 1.03 – 1.86 0.03
36 – 50 1,497 66.6 1.24 1.12 – 1.37 < 0.001 1.23 1.03 – 1.47 0.02
51 – 65 4,774 65.7 1.21 1.13 – 1.30 < 0.001 1.15 1.02 – 1.29 0.02
66 – 75 4,172 61.3 (ref) (ref)
76+ 1,579 54.6 0.77 0.71 – 0.85 < 0.001 0.79 0.71 – 0.88 < 0.001
Ethnicity
White 11,705 62.7 (ref) (ref)
Mixed 88 66.7 1.17 0.81 – 1.67 0.41 0.77 0.48 – 1.24 0.28
Asian/Asian British 254 59.1 0.84 0.69 – 1.02 0.08 0.71 0.54 – 0.92 0.01
Black/Black British 201 55.7 0.76 0.61 – 0.94 0.01 0.63 0.47 – 0.83 0.001
Other 68 63.6 1.02 0.69 – 1.53 0.91 0.73 0.43 – 1.26 0.26
Long-standing conditions b
None 8,127 63.7
Deafness/hearing impairment 991 60.4 0.92 0.83 – 1.03 0.13 1.04 0.92 – 1.19 0.54
Blindness/partially sighted 220 63.4 1.06 0.85 – 1.33 0.60 1.09 0.78 – 1.52 0.61
Physical condition 1,519 61.2 0.92 0.84 – 1.01 0.06 0.91 0.82 – 1.01 0.08
Learning disability 45 54.9 0.73 0.47 – 1.15 0.17 0.66 0.33 – 1.35 0.26
Mental health condition 219 61.7 0.97 0.78 – 1.21 0.80 0.99 0.71 – 1.40 0.99
Long-standing illness c 1,348 59.4 0.86 0.78 – 0.94 0.001 0.86 0.77 – 0.97 0.01
Clinical level factors
Tumour group n % OR 95 % CI p-value ORadj
a 95 % CI p-value
Brain/CNS 171 67.1 1.63 1.24 – 2.15 0.001 1.42 0.91 – 2.22 0.12
Breast 2,769 56.9 (ref) (ref)
Colorectal / Lower GI 1,709 64.0 1.33 1.21 – 1.47 < 0.001 1.34 1.14 – 1.59 0.001
Gynaecological 621 61.1 1.19 1.04 – 1.37 0.01 1.30 1.06 – 1.59 0.01
Haematological 2,753 71.7 1.95 1.78 – 2.14 < 0.001 1.98 1.65 – 2.38 < 0.001
Head and Neck 430 65.3 1.43 1.20 – 1.70 <0.001 1.28 0.96 – 1.71 0.09
Lung 864 59.9 1.17 1.03 – 1.32 0.01 1.14 0.95 – 1.37 0.15
Other 547 65.7 1.49 1.27 – 1.74 < 0.001 1.38 1.09 – 1.74 0.01
Prostate 1,080 60.5 1.18 1.05 – 1.32 0.004 1.15 0.94 – 1.41 0.18
Sarcoma 161 70.3 1.86 1.38 – 2.50 < 0.001 1.58 0.91 – 2.76 0.10
Skin 183 57.9 1.07 0.85 – 1.36 0.56 1.00 0.64 – 1.56 0.99
Upper GI 819 58.9 1.10 0.98 – 1.25 0.12 1.04 0.86 – 1.26 0.70
Urological 575 54.9 0.91 0.79 – 1.04 0.17 0.97 0.79 – 1.20 0.80
Time since 1st treatment
< 1 year 7,355 60.1 (ref) (ref)
1–5 years 3,820 66.8 1.31 1.23 – 1.40 < 0.001 1.22 1.10 – 1.34 < 0.001
> 5 years 1,199 67.3 1.39 1.25 – 1.55 < 0.001 1.25 1.09 – 1.44 0.002
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Table 3 Characteristics associated with research participation (Continued)
Trust level factors
Trust type n % OR 95 % CI p-value ORadj
a 95 % CI p-value
Small acute 825 59.6 1.02 0.90 – 1.15 0.84 1.02 0.83 – 1.23 0.92
Medium acute 2,329 59.2 0.99 0.91 – 1.08 0.79 0.96 0.83 – 1.12 0.62
Large acute 3,465 59.3 (ref) (ref)
Specialist 1,109 69.1 1.55 1.37 – 1.75 < 0.001 1.40 1.16 – 1.70 0.001
Teaching 4,954 65.3 1.30 1.21 – 1.40 < 0.001 1.31 1.12 – 1.52 0.001
Foundation status
No 5,254 61.2 (ref) (ref)
Yes 7,428 63.1 1.08 1.02 – 1.14 0.01 1.02 0.91 – 1.15 0.69
Location
Outside London 10,170 61.4
London 2,512 66.5 1.25 1.16–1.35 < 0.001 1.12 0.95 – 1.31 0.17
Table 3 shows the characteristics of respondents who had taken part in cancer research, and the association of these characteristics with research participation by
logistic regression. 2.4 % of respondents (n = 491) did not state whether or not they went on to take part in research following discussions with staff
GI = gastrointestinal; CNS = central nervous system
a Adjusting for patient level (i.e. gender, age, ethnicity, specific longstanding conditions, sexual orientation, employment status), clinical level (i.e. tumour group,
time since first treatment, response to treatment) and trust level factors (i.e. trust type, foundation status, London location)
b The reference category for specific long-standing conditions was not having that long-standing condition
c Such as (but not limited to) HIV, diabetes, chronic heart disease or epilepsy
Fig. 2 Factors associated with discussion about and participation in cancer research. Patient, clinical and trust level factors significantly associated
with research discussion and participation. Adjusted odds ratios (from Tables 2 and 3) are presented in brackets
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research. We identified a number of demographic, clinical
and trust level factors that were associated with discussion
and participation and, taken together, these factors meant
that certain groups of patients were less likely to have ac-
cess to any benefits associated with research.
Analysis of NCPES data shows that women, older pa-
tients and those with long-standing conditions were sig-
nificantly less likely to have discussed research. Some of
the observed variation will be due to numbers of avail-
able studies for specific tumour groups or other eligibil-
ity criteria. However, it has been shown that staff do not
always discuss taking part in research with all eligible
patients [13], for example they are less likely to discuss
enrolment with patients who they believe are unlikely to
accept [14]. The negative associations between research
discussion and age, gender and having a long-standing
condition that we observed may therefore be a result of
preconceptions which may have influenced, uncon-
sciously or otherwise, the patients that staff chose to
approach. Staff may not approach some patients who
they consider may be difficult to enrol or accommodate
because they require modified information sheets, non-
standard appointment times or interpreters that would
increase costs and create difficulties in meeting study
deadlines [15]. Patients may also be excluded if they are
thought to be less likely to comply with the study
requirements or more likely to have co-morbidities that
could confuse research results [16]. Such pragmatic con-
siderations may have contributed to the significantly
lower proportions of older patients and those with long-
standing conditions who reported discussions about
research participation. Alternatively, altruistic desires
not to burden patients with the demands of participating
in a research study [17] could have affected the selection
of potential participants. However, it is important to
consider the effect of these patterns of recruitment,
whether well-intentioned or simply pragmatic. Not only
do they bar some patients from the potential benefits of
participating in research, but the under-representation
of particular categories of patient can also affect the
external validity of study results. If a research population
does not accurately represent the target population, find-
ings may not be generalizable to those in need or as effi-
cacious when applied [18, 19]. The observed exclusion
from discussions about research of elderly patients and
those with increasingly common long-standing illnesses
(such as diabetes or coronary heart disease) is a particu-
lar concern as improved survival rates and the current
demographic shift means that increasing numbers of
cancer patients are living longer with complex co-
morbidities. Yet it appears that this growing proportion
of the target population is under-represented in trials, a
factor which may hinder the development of appro-
priate, acceptable and effective treatments in the future.
Adjusting for other confounding factors, breast, colorec-
tal/lower GI, haematological and prostate patients were
more likely than others to have had discussions about re-
search. Such variation is to be expected given that the avail-
ability and funding of ongoing studies [20] is not evenly
distributed between tumour groups; for example, there are
currently twice as many trials in recruitment phase for
breast cancer in the UK as there are for gynaecological can-
cers (113 vs 55) [21]. Trust type also influenced whether or
not staff discussed research participation with patients; pa-
tients attending specialist and teaching hospitals were more
likely to have had discussions. This finding may reflect dif-
ferences in staff attitudes to research [22] and revenue
streams at these institutions
Participation was high among those who had discussed
taking part in research; however, there was significant vari-
ation in participation by patient, clinical and trust level
factors. Older patients and those with co-morbidities were
significantly less likely to participate but the observed
negative association may reflect patient preferences or in-
eligibility for recruitment due to current treatment regi-
mens [23]. Asian and Black patients were also significantly
less likely to participate in research than white patients.
Since our multivariate analysis adjusted for factors likely
to be related to ineligibility (i.e. age, long-standing ill-
nesses) it is possible that the observed differences by eth-
nicity indicate variation in willingness to participate.
Language, cultural beliefs related to health and illness and
mistrust of medical research (particularly among Black pa-
tients) have been identified elsewhere as barriers to re-
search participation among ethnic minorities [24, 25].
Potential recall bias must also be considered when
interpreting interview data. Also, findings from patients
with breast cancer may not be applicable to other
tumour groups. Despite these limitations, results from
our interviews aided our interpretation of survey data
and our understanding of the relationship between dis-
cussing and participating in research. For example, trust
in clinicians motivated research participation among the
women with breast cancer we interviewed who reported
that they valued the opinions of clinicians highly during
decision-making. Just one patient expressed mistrust of
the motivations of research and declined to participate
in any biomedical studies. Our interviews with breast
cancer patients also indicated that the nature and poten-
tial side effects of a study were important determinants
of participation [26], as was the timing of discussions;
sometimes women who declined to participate in a trial
later joined another that they considered more accept-
able or which was enrolling at a time when they felt bet-
ter able to cope. Of the women who did not participate
in research, some reported discussions about taking part
and had been willing to do so until it was discovered
they were ineligible due to their current health status,
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treatment history or tumour sub-group. When discuss-
ing participation in research with patients, staff may find
it helpful to consider and anticipate the impact of ineli-
gibility to a study that might have provided a patient
with a source of hope [27, 28].
Conclusion
For the first time, data from an established national sur-
vey has been used to investigate inequalities in access to
research participation among a large number of cancer
patients. Our analysis shows that cancer patients in Eng-
land do not have equitable access to research participa-
tion and that patients are not equally likely to take part
if presented with the opportunity. Further work with
staff to identify the causes of the observed variation and
to develop strategies to reduce the inequalities in access
to research participation will be valuable. Understanding
and addressing the barriers to participation among older
patients, ethnic minorities and those with long-standing
illnesses is also important so as to ensure, firstly, that
there is equity regarding the potential benefits of re-
search participation and, secondly, that findings from a
research study are applicable to the target population in
need under the translational model.
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